Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. more
Time Frame | MURA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 13.74% | 0.49% | -0.42% |
1-Month Return | 0.26% | -3.1% | -2.2% |
3-Month Return | 13.74% | -8.59% | 2.38% |
6-Month Return | 27.96% | -4.57% | 5.1% |
1-Year Return | -24.9% | -0.94% | 23.79% |
3-Year Return | 2.37% | 2.88% | 26.66% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | 1.47M | 1.54M | 2.57M | [{"date":"2021-12-31","value":57.42,"profit":true},{"date":"2022-12-31","value":59.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Profit | (1.47M) | (1.54M) | (2.57M) | [{"date":"2021-12-31","value":-147400000,"profit":false},{"date":"2022-12-31","value":-154000000,"profit":false},{"date":"2023-12-31","value":-256700000,"profit":false}] | ||
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] | ||
Operating Expenses | 175.37M | 195.15M | 192.07M | [{"date":"2021-12-31","value":89.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.42,"profit":true}] | ||
Operating Income | (175.37M) | (195.15M) | (194.64M) | [{"date":"2021-12-31","value":-17536500000,"profit":false},{"date":"2022-12-31","value":-19514600000,"profit":false},{"date":"2023-12-31","value":-19463800000,"profit":false}] | ||
Total Non-Operating Income/Expense | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Pre-Tax Income | (175.37M) | (195.15M) | (195.29M) | [{"date":"2021-12-31","value":-17536500000,"profit":false},{"date":"2022-12-31","value":-19514600000,"profit":false},{"date":"2023-12-31","value":-19528700000,"profit":false}] | ||
Income Taxes | 68.00K | 4.88M | 12.16M | [{"date":"2021-12-31","value":0.56,"profit":true},{"date":"2022-12-31","value":40.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income After Taxes | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income From Continuous Operations | (175.43M) | (200.03M) | (207.45M) | [{"date":"2021-12-31","value":-17543300000,"profit":false},{"date":"2022-12-31","value":-20003000000,"profit":false},{"date":"2023-12-31","value":-20744700000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (175.43M) | (200.03M) | (207.45M) | [{"date":"2021-12-31","value":-17543300000,"profit":false},{"date":"2022-12-31","value":-20003000000,"profit":false},{"date":"2023-12-31","value":-20744700000,"profit":false}] | ||
EPS (Diluted) | - | - | (3.57) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-356.73,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
MURA | |
---|---|
Cash Ratio | 7.04 |
Current Ratio | 7.38 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MURA | |
---|---|
ROA (LTM) | -81.05% |
ROE (LTM) | -178.34% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MURA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MURA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.38 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Mural Oncology plc (MURA) share price today is $3.89
Yes, Indians can buy shares of Mural Oncology plc (MURA) on Vested. To buy Mural Oncology plc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MURA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mural Oncology plc (MURA) via the Vested app. You can start investing in Mural Oncology plc (MURA) with a minimum investment of $1.
You can invest in shares of Mural Oncology plc (MURA) via Vested in three simple steps:
The 52-week high price of Mural Oncology plc (MURA) is $5.62. The 52-week low price of Mural Oncology plc (MURA) is $2.87.
The price-to-earnings (P/E) ratio of Mural Oncology plc (MURA) is
The price-to-book (P/B) ratio of Mural Oncology plc (MURA) is 0.38
The dividend yield of Mural Oncology plc (MURA) is 0.00%
The market capitalization of Mural Oncology plc (MURA) is $66.36M
The stock symbol (or ticker) of Mural Oncology plc is MURA